GERMANTOWN, Md., April 08, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a vertically integrated biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGT) through its Point-of-Care (POCare) Platform, today announces a joint venture agreement with RevaTis S.A. The goal of the JV is to advance the development of autologous therapies, including in-licensed therapies through Orgenesis’s partners, utilizing and banking muscle-derived mesenchymal stem cells (mdMSC) as a source of exosomes and other cellular products. RevaTis has developed a patented technique to obtain mdMSCs through a minimally invasive muscle micro-biopsy and produce mdMSCs utilizing a turnkey isolator system.
The goal of the JV is to build upon RevaTis’ initial success in animals to develop therapies and advance human trials by leveraging Orgenesis’s technical, clinical and regulatory expertise, as well as Orgenesis’s POCare Technologies. These technologies include automated/closed-systems, 3D printing, and bioreactor technologies. The JV will be dedicated to developing RevaTis' technology in humans.
Didier Serteyn, DVM, PhD, CEO of RevaTis, commented, “We are delighted to partner with Orgenesis, as we seek to advance a variety of promising cell therapies built around our proprietary processes to collect and produce mdMSCs. We selected Orgenesis as a result of their extensive experience in the field of autologous cell therapies, including technical, clinical and regulatory expertise. We expect that this will be valuable as we aim to advance our platform through commercialization. Importantly, Orgenesis’s unique POCare Platform provides a global network of hospitals and research institutes through which we can conduct clinical trials, with a goal to develop life-saving therapies.”
Vered Caplan, CEO of Orgenesis, further noted, “RevaTis’s technologies are highly differentiated and ideally suited for our Cell & Gene Biotech Platform. We believe that this exclusive partnership with RevaTis further validates the significant value proposition of the Orgenesis vertically integrated business model. This model allows us to streamline the entire process of therapeutic development and delivery of cell therapies within the patient care setting through our Cell & Gene Biotech Platform. In addition, RevaTis has existing partnerships with research institutions in the US, the Middle East and India that will be highly complementary to our own POCare Network. We look forward to utilizing the Orgenesis Cell & Gene Biotech Platform with a goal to lower the costs and accelerate the timeline of bringing these innovative therapies through the clinic and potentially into commercialization.”
About RevaTis
RevaTis, a spin-off from Liege University in Belgium, was founded in 2013 and is dedicated to advanced regenerative medicine and cell therapy. RevaTis has developed an innovative and patented technique to obtain pluripotent mesenchymal stem cells through a minimally invasive muscle micro-biopsy. RevaTis’ technique involves the use of an aseptic isolator in a “turnkey” system, which meets GMP standards. Additional information is available at: https://www.revatis.com/.
About Orgenesis
Orgenesis is a vertically integrated biotech company that is lowering costs, accelerating commercialization, and transforming the delivery of life saving cell and gene therapies (CGT). The Company’s CGT Biotech Platform consists of: (a) POCare Therapies, a therapeutic pipeline comprised of proprietary and licensed CGTs; (b) POCare Technologies, an integrated suite of proprietary and in-licensed technologies designed to enable onsite production and administration of CGTs within the patient care setting; and (c) POCare Network, a growing network of research institutions and hospitals through which the Company in licenses technologies or CGTs and out licenses POCare Therapies/CGTs and POCare Technologies. The Company also provides regulatory, pre-clinical/clinical development, and training services to support the POCare Network, either directly or through regional partners. Additional information is available at: www.orgenesis.com.
